Liver cancer is the sixth bigger cancer killer in the EU, claiming the lives of almost 60,000 people per year.
News
NICE nod for Blincyto
Amgen has a confidential commercial arrangement which will make the drug available to the NHS with a discount.
Positive results for AZ’ Lokelma in hyperkalaemia
The company announced a statistically significant and clinically meaningful improvement from its Phase IIIb DIALIZE trial.
Modified vaccinia virus shows potential in fighting sarcoma tumours
The cancer-killing virus with immunotherapy could effectively treat the advanced cancers.
NHS Long Term Plan stunted by lack of workforce investment
A final NHS People Plan will be published following the outcome of the Comprehensive Spending Review.
Sanofi, Google link up for new healthcare innovation lab
The collaboration will leverage deep analytics across data sets to better understand key diseases.
Owlstone Medical explores breath-based testing for more diseases
The company will use ‘Exogenous Volatile Organic Compound Probes’.
Venue announced for the 2019 Marketer of the Year, Communications Team of the Year and the Sales Awards
The Chelsea Harbour Hotel has been confirmed to host the gala dinner and awards ceremonies for the three competitions on 14th November.
RCGP plea to avoid no-deal Brexit
A no-deal Brexit should be avoided ‘at any cost’, according to the College
Greater Manchester joins Cities Changing Diabetes initiative
The city is the second in the UK to join the Novo Nordisk led partnership programme
Amgen unveils five-year survival data for Blincyto
Early achievement of complete molecular remission with Blincyto is linked with prolonged survival, researchers note
AZ’ Calquence shows PFS benefit in CLL patients
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
GSK, Uni of California pair up to advance genomic research
The LGR will receive up to $67 million in funding over a five-year period.
Outdated technology systems still ‘limiting’ UK patient care
Over a third (36%) of respondents’ staff have asked for faster digital technology systems.
Rituxan hits endpoints in late-stage skin disease trial
The drug demonstrated superiority to current standard-of-care to CellCept.
